

Jan 14 . 2004

CURRICULUM VITAE

NAME:	PETER TUGWELL	
NATIONALITY:	Citizenship - Canadian and British	
MARITAL STATUS:	Married	
DATE OF BIRTH:	March 30, 1944	
MEDICAL SCHOOL:	Royal Free Hospital Medical School London University, London, England	
QUALIFICATIONS:	M.R.C.S., L.R.C.P.	- 1969
	M.B.B.S. (London)	- 1969
	M.R.C.P. (UK)	- 1971
	L.M.C.C.	- 1976
	M.D. (London)	- 1976
	F.L.E.X. (Michigan)	- 1976
	F.R.C.P.C.	- 1976
	M.Sc.(Clinical Epidemiology)	- 1977
	F.A.C.P.	- 1984
	F.R.C.P. (UK)	- 1987

APPOINTMENTS:

July - Dec. 1969	Royal Free Hospital, London, England House Physician to Medical Unit (Dr. N. McIntyre and Prof. S. Sherlock).
Jan. - June 1970	West Middlesex Hospital, London, England, House Surgeon to Mr. I. Cour- Palais.
July - Dec. 1970	Whittington Hospital, London, England Post Registration House Physician to Dr. B. Hoffbrand.
Jan. - Oct. 1971	Whittington Hospital, London, England Sr. House Physician to Dr. P.D.B. Davis.
Oct. 1971 - Sept. 1972	Ahmadu Bello University Hospital, Zaria, Nigeria. Registrar in Medicine to Prof. E.H.O. Parry.
Oct. 1972 - July 1974	Ahmadu Bello University Hospital, Zaria, Nigeria. Clinical Research Registrar to Prof. E.H.O. Parry.
July 1975 - July 1976	McMaster University, Chief Resident in Internal Medicine.
July 1976 - June 1977	McMaster University, Clinical Fellow in Rheumatology.
July 1977 - June 1980	Assistant Prof. in Department of Clinical Epidemiology and Biostatistics, and Dept. of Medicine, McMaster University.
July 1977 - June 1991	Attending Physician, Division of Rheumatology, Chedoke-McMaster Hospital.
July 1978 - June 1979	Provincial Health Research Scientist.
July 1979 - June 1989	Chairman, Dept. of Clinical Epidemiology and Biostatistics, McMaster University.
July 1980 - June 1984	Associate Prof. Dept. of Clinical Epidemiology and Biostatistics, McMaster University.
July 1984 - June 1991	Professor, Dept. of Clinical Epidemiology and Biostatistics and Dept. of Medicine, McMaster University.
Nov. 1984 - May 1985	Visiting Professor, University of Sydney, Australia.
May 1987 - June 1991	Director and Regional Coordinator for McMaster Regional Rheumatology Program.
Dec. 1988 - June 1991	Chief of Internal Medicine, Chedoke Hospital, Chedoke-McMaster Hospitals; Head of Rheumatology, Chedoke-McMaster Hospitals.
July 1989 - June 1991	Director of McMaster Centre for Arthritic Diseases.
Jan 1990 - July 1991	Director, Rheumatology Day Hospital, Chedoke Hospital, Chedoke-McMaster Hospitals.
July 1991 - July 2001	Physician-in-Chief , Department of Medicine, Ottawa General Hospital and 1998-2001 for the Ottawa Hospital.

July 1991 - July 2001	Professor and Chairman, Department of Medicine, University of Ottawa.
July 2001- present	Director, Centre for Global Health, Institute of Population Health, University of Ottawa
Jan 2002 - 2009	Canada Research Chair

NATIONAL/INTERNATIONAL COMMITTEES:

1977 - 1982	Member, Demonstration Model Grants Review Committee, Ministry of Health, Ontario.
1977 - 1979	Chairman, Regional Service Program, McMaster University.
1979 - 1982	Member, Ontario Council of Health Task Force on High Technology.
1980 - 1986	Member, Hospital Medical Research Institute Committee on Quality of Care.
1980 - 1991	Director, McMaster International Clinical Epidemiology Training Program.
1980 - 1984	Member, Population Health Task Force, Canadian Institute for Advanced Research.
1982 - 1985	Member, Ontario Council of Health Advisory Panel.
1982 - 1984	Member, Research Grants Panel, The Arthritis Society.
1982 - 1987	Member, Clinical Research Committee, Pan-American League against Rheumatism.
1982 - 1984	Fellowship Examiner, Royal College of Physicians and Surgeons of Canada.
1982 - 1984	Member, NMR Advisory Panel, The Ontario Cancer Institute.
1983 - 1988	Co-Director, Biometry Centre for Ontario Clinical Oncology Trials Group.
1984 - 1994	Member, Board of Directors, Canadian Society for Tropical Medicine and International Health. [President 1989 - 1991]
1985 - 1989	Member, Editorial Board, Annals of Internal Medicine.
1986 - 2002	Editorial Board, Postgraduate Medical Journal (UK).
1986 - 1989	American College of Physicians Scientific Program Sub-Committee.
1986 - 1988	Member, Research Advisory Panel, Ontario Cancer Treatment & Research Found.
1986 - 1989	Member, Council of Canadian Society for Clinical Investigation.
1986 - 1987	Member, Ontario Health Research Personnel Committee.
1989 - 1991	Member, Review Committee, Pharmacoepidemiology Selections Program: The American College of Preventive Medicine and the Burroughs Wellcome Research Foundation.
1989 - 1997	Chairman, Epidemiology Committee, International League of Associations for Rheumatology.
1990 - 1991	Member of Board of Directors, Ontario Workers' Compensation Institute.
1990 - 1995	Member, Advisory Committee, University Partnerships Project, Network of Community-Oriented Educational Institutions for Health Sciences.
1991 - 1992	Canadian Hospital Association: Member of Expert Working Group for the National Health Policy Reform (Vision) Project.

1992 - 1996	Member, Health Policy Committee, Royal College of Physicians and Surgeons of Ontario.
1992 - 1994	Member, External Advisory Board, Lawson Research Institute, University of Western Ontario, London, Ontario.
1993 - 1994	Chairman, Health Protection Policy Review Team, Health Protection Branch, Health and Welfare, Canada.
1993 - 1996	Member, Saskatchewan Health Methodology Advisory Panel, Regina, Saskatchewan.
1994 - 1996	Subcommittee of the Future of Academic Health Sciences Centres, Provincial Coordinating Committee on Community and Academic Relations (PCCCAR), Ontario Ministry of Health.
1994 - 1995	Member, Task Force on Strengthening Regional Innovation and Business Development, Ontario Ministry of Health.
1994 - 1996	Member, Committee on Reconfiguration of Local Health Services, Ottawa-Carleton Regional District Health Council.
1994 - 1996	Member, Hospital Services Task Group, Ottawa-Carleton Regional District Health Council.
1994-	Director, WHO Collaborating Centre on Health Technology Assessment
1994 -	Chair, Editorial Group of the Cochrane Collaboration Review Group for Musculoskeletal Disease.
1994 - 1996	Chair, CANMEDs Committee for new training requirements for subspecialties to meet societal needs, Royal College of Physicians and Surgeons of Canada.
1995 - 1999	Member, Health Advisory Committee, Alberta Heritage Foundation for Medical Research, Edmonton, Alberta.
1995 - 1997	Representative for the University of Ottawa, Steering Committee, Canadian University Consortium for Health in Development (CUCHID).
1995 - 1998	Chair, Education Committee, Canadian Association of Professors of Medicine.
1996 -	Member, Editorial Board: The Journal of Quality and Clinical Practice.
1997 -	Member, Editorial Board: Clinical and Experimental Rheumatology.
1997 -	Member, Editorial Board: American Journal of Medicine.
1997 - 2000	Member, Publication Committee, American College of Physicians.
1998-2000	Chair, Research SubCommittee, International Clinical Epidemiology Network.
1999 - 2000	President, Canadian Association of Professors of Medicine.
1999 - 2000	Member, Strategic Action working Group on Osteoporosis, The Ontario Women's Health Council.
1999 - 2000	Coordinator, Project to develop an international index of Health Research, Council on Health Research and Development, Geneva.

2000 -2001	Member, Committee on Strategies for Small Number Participant Clinical Research Trials, Institute of Medicine, USA.
2000 - 2001	Member, Editorial Board, Clinical Drug Investigation & BioDrugs, Adis International.
2001-2004	Member, Advisory Committee, Musculoskeletal Disorders, Biomed Central
2002 -	North American Editor, Journal of Clinical Epidemiology
2002 - 2005	Member, Oversight Committee, Canadian Medical Association Journal
2002	Member, Steering Committee, The Canadian Coalition for Global Health Research
2003	Member, Editorial Board, The International Journal of Technology Assessment in Health Care.
2003-2005	Honorary Professor, School of Population Health, The University of Queensland
2003	Secretary General, CanUSACLEN

UNIVERSITY OF OTTAWA COMMITTEES:

Faculty of Medicine:

1991 - 1992	Chairman, Faculty AFP Committee
1991 - 2001	Member, Faculty Council Committee Member, Faculty Advisory Board Member, Special Committee on GFT Arrangements
1992 - 1995	Chairman, Ad Hoc Tri-Faculty Committee on International Health Chairman, Liaison Committee for the Queen's-U of O Health Projects
1993 - 1997	Co-Chairman, Strategic Planning Academic Program Council on Health and Wellness
1993 - 2001	Member, Advisory Committee of the Institute for Research and Education in Palliative Care at the Elisabeth-Bruyère Health Centre

Department of Medicine:

1991 - 2001	Chair, Advisory Board Chair, Departmental AFP Committee Chair, TPC/Executive Committee Member, Clerkship/Education Committee Member, Rheumatic Disease Unit
-------------	---

OTTAWA HOSPITAL COMMITTEES:

1991 - 2001	Member, Ottawa Hospital Medical Advisory Committee
1991 - 1998	Chair, Ottawa Hospital, Dept. of Medicine, Medical Associates Executive Committee
1991 - 2001	Chair, Ottawa Hospital, Dept. of Medicine, Division/Section Heads Committee
1992 - 1994	Member, Ottawa Hospital, Research Planning Committee

ORGANIZATIONAL MEMBERSHIPS:

Society for Epidemiologic Research

International Epidemiological Association

American Federation for Clinical Research

American Rheumatology Association

Canadian Rheumatism Association

Sydenham Society

Canadian Society for Clinical Investigation

Society for Medical Decision Making

American College of Physicians

The Canadian Public Health Association

The Canadian Society for International Health

AWARDS:

1997 Researcher of the Year Award, Ottawa General Hospital

2000 Dr. J. David Grimes Award, Research Career Achievement, Loeb Health Research Institute at the Ottawa Hospital

EDUCATION:

Graduate Courses taught:

1995-6	International Health and Development, Carleton University
1995-	Health Technology Assessment, University of Ottawa
1999-	International Health and Development, University of Ottawa
2000	Health Technology Assessment, University of Ottawa

RESEARCH INTERESTS:

1. Evaluation of therapeutic interventions, diagnostic tests and their application to evidence based medicine.
2. Development and evaluation of strategies for assessing health technologies, quality of life, utilities and economic evaluation.
3. Evaluation of educational strategies and strategies for dissemination of evidence to consumers, clinicians and policy makers.

PUBLICATIONS:

- Thesis: June 1976 M.D. Thesis (London, England)
 Clinical, Epidemiological and Immunological Aspects of Pneumococcal Infection
 in the African Savanna
 Supervisor - Prof. S. Sherlock and Prof. E.H.O. Parry
- June 1977 M.Sc. Thesis (McMaster University)
 Process Measures of Quality of Care
 Supervisor - Dr. D. L. Sackett

BOOKS:

1. Feeny D., Guyatt G.H., Tugwell P. Health Care Technology: Effectiveness, Efficiency and Public Policy; Montreal, The Institute for Research on Public Policy; 1986.
2. Sackett, D.L., Haynes, R.B., Guyatt, G.H., Tugwell, P. Clinical Epidemiology: A Basic Science for Clinical Medicine; Boston, Little, Brown and Company; 1st Edition in 1985 and 2nd Edition in 1991.
3. Tugwell P, Boers M, Brooks P, Shea B, Simon L, Strand V . Evidence Based Rheumatology. BMJ Books, November 2003.

ARTICLES, MONOGRAPHS AND BOOK CHAPTERS:

1. Tugwell P, James SL. Peripheral Neuropathy with Ethambutol. Postgraduate Medical Journal. 1972; 48:667-670.
2. Tugwell P, Southcott D, Walmesley P. Free Perforation of the Colon in Crohn's Disease. The British Journal of Clinical Practice. 1972; 26(1):44-45.
3. Tugwell, P. Glucose-6-Phosphate-Dehydrogenase Deficiency in Nigerians with Jaundice Associated with Lobar Pneumonia. The Lancet. 1973; 1:968-970.
4. Tugwell, P. Seasonal Variation of Pneumococcal Infections in the African Savanna. West African Medical Journal. 1973; 5:34.
5. Whittle HC, Davidson N.McD, Greenwood BM, Warrell D, Tomkins A, Tugwell P, Zalin A, Parry EHO, Bryceson ADM, Brueton M, Duggan M, Rajokovic A. Trial of Chloramphenicol for Meningitis in Northern Savanna of Africa. British Medical Journal. 1973; 3:379-381.
6. Tugwell P, Greenwood BM. Bacteriological Findings in Pneumonia (Letter). The Lancet. 1974; 1:95.
7. Greenwood BM, Tugwell P, Whittle HC. Microbial Antigen Detection. (Letter). The Lancet. 1974; 2:598-599.
8. Whittle HC, Tugwell P, Egler LJ, Greenwood BM. Rapid Bacteriological Diagnosis of Pyogenic Meningitis by Latex Agglutination. The Lancet. 1974; 2:619-621.
9. Brueton M, Tugwell P, Whittle HC, Greenwood BM. Fibrin Degradation Products in the Serum and Cerebrospinal Fluid of Patients with Group A Meningococcal Meningitis. Journal of Clinical Pathology. 1974; 27:402-404.
10. Tugwell P, Greenwood BM. Pneumococcal Antigen in Lobar Pneumonia. Journal of Clinical Pathology. 1975; 28:118-123.

11. Harrison BDW, Tugwell P, Fawcett IW. Tuberculin Reaction in Adult Nigerians with Sputum-Positive Pulmonary Tuberculosis. *The Lancet*. 1975; 1:421.
12. Whittle HG, Greenwood BM, Davidson N.McD, Tomkins A, Tugwell P, Warrell DA, Zalin A, Bryceson ADM, Parry EHO, Brueton M, Duggan M, Oomen JMV, Rajokovic AD. Meningococcal Antigen in Diagnosis and Treatment of Group 'A' Meningococcal Infections. *American Journal of Medicine*. 1975; 58:823-828.
13. Harrison BDW, Tugwell P, Fawcette IW. Tuberculin Reaction in Sputum-Positive Pulmonary Tuberculosis. *The Lancet*. 1975; 421.
14. Norman G, Tugwell P. Resident Performance Evaluation - A Comparison Among Members of the Health Care Team. *Proceedings of the Fifteenth Annual Conference on Research in Medical Education: The Association of American Medical Colleges*. 1976; 15:114-119.
15. Williams AO, Tugwell P, Edington GM. Glucose-6-Phosphate Dehydrogenase Deficiency and Lobar Pneumonia: Fine Structure of the Liver. *Archives of Pathology*. 1976; 100:25.
16. Tugwell P, Greenwood BM, Warrell DA. Pneumococcal Meningitis: A Clinical and Laboratory Study. *Quarterly Journal of Medicine*. 1976; 45:583.
17. Tugwell P, Williams AO. "Jaundice Associated with Lobar Pneumonia" A Clinical Laboratory and Histological Study. *Quarterly Journal of Medicine*. 1977; 46:97.
18. Tugwell P. A Methodological Perspective on Process Measures of the Quality of Medical Care. *Clinical and Investigative Medicine*. 1979; 2:113.
19. Gilbert JR, Evans CE, Haynes RB, Tugwell P. Predicting Compliance with a Regimen of Digoxin Therapy in Family Practice. *Canadian Medical Association Journal*. 1980; 123:119-122.
20. Tugwell P, Sackett DL, Haynes RB. On the Critical Assessment and Clinical Applicability of the Rheumatology Literature. *Journal of Rheumatology*. 1980; 7:765-771.
21. Chambers LW, Sibley JC, Spitzer WO, Tugwell P. Quality of Care Assessment: How to set up and use an Indicator Condition. *Clinical and Investigative Medicine/Medicine Clinique et Experimentale*. 1981; 4(1):41-50.
22. Sackett DL, Haynes RB, Tugwell P. Evaluation: Requirements for Clinical Application. Chapter in: *Coping with the Biomedical Literature*, Praeger, 1981; pp.123-157.
23. Department of Clinical Epidemiology and Biostatistics: How to Read Clinical Journals: I. Why read them and how to start reading them critically. *Canadian Medical Association Journal*. 1981; 124:555-558.
24. Department of Clinical Epidemiology and Biostatistics: How to Read Clinical Journals: II. To learn about a diagnostic test. *Canadian Medical Association Journal*. 1981; 124:703-710.
25. Department of Clinical Epidemiology and Biostatistics: How to Read Clinical Journals: III. To learn about the clinical course and prognosis of disease. *Canadian Medical Association Journal*. 1981; 124:869-872.
26. Department of Clinical Epidemiology and Biostatistics: How to Read Clinical Journals: IV. To determine etiology or causation. *Canadian Medical Association Journal*. 1981; 124:985-990.
27. Department of Clinical Epidemiology and Biostatistics: How to Read Clinical Journals: V. To distinguish useful from useless or even harmful therapy. *Canadian Medical Association Journal*. 1981; 124:1156-1162.

28. Ellis P, Fox K, Johnson B, Moran J, Ogilvie M, Tugwell P, Woo C. Patient Care Appraisal Handbook. Ontario Hospital Association. April 1982.
29. Norman GR, Tugwell P, Feightner JW. A Comparison of Resident Performance on Real and Simulated Patients. *Journal of Medical Education*. 1982; 57:708-715.
30. Bombardier C, Tugwell P. A Methodologic Framework to Develop and Select Indices for Clinical Trials: Statistical and Judgmental Approaches. *Journal of Rheumatology*. 1982; 9:753-757.
31. Tugwell P, Bombardier C. A Methodologic Framework for Developing and Selecting Endpoints in Clinical Trials. *Journal of Rheumatology*. 1982; 9:758-762.
32. Bombardier C, Tugwell P, Sinclair A, Dok C, Anderson G, Buchanan W. Preference for Endpoint Measures in Clinical Trials: Results of Structured Workshops. *Journal of Rheumatology*. 1982; 9:798-801.
33. Chambers LW, McDonald LA, Tugwell P, Buchanan WW, Kraag G. The McMaster Health Index Questionnaire as a Measure of Quality of Life for Patients with Rheumatoid Disease. *Journal of Rheumatology*. 1982; 9:780-784.
34. Tugwell P. Epidemiology and Evaluation of Health Services: An International Perspective. In *Population-Based Medicine*. Lipkin M, Jr, Lybrand WA (Eds.). Praeger, New York. 1982; pp.57-65.
35. Tugwell P, Bennett KJ. In *Proceedings of a Conference on Health and Health Care*. "The Process of Critical Appraisal and its Applications to Issues in the Health Field." Montebello, Canada. March 1982; pp.45-63.
36. Tugwell P. "The McMaster International Clinical Epidemiology Program". In: *Teaching Clinicians Epidemiology: Problems and Prospects*. New York, Rockefeller Foundation. 1982; pp.51-53.
37. Tugwell P. "Learning Materials Based on Developing Country Experiences". In: *Teaching Clinicians Epidemiology: Problems and Prospects*. New York, Rockefeller Foundation. 1982; pp.115-116.
38. Tugwell P, Buchanan W, Bombardier C. Outcome Measures for Clinical Trials in Rheumatology. *European Journal of Rheumatology and Inflammation*. 1983; 6(2):140-141.
39. Leung F, Tugwell P. Polyarthritis that Defied a Decade of Treatment. *Hospital Practice*. May 1983; pp.96-108.
40. Buchanan WW, Tugwell P. "Traditional Assessment of Articular Diseases". Chapter In: *Clinics in Rheumatic Diseases*, Klippel JH, Decker JL (Eds.). WB Saunders Co. Ltd., 1983; Vol. 9(3), pp.515-529.
41. Huskisson EC, Sturrock RD, Tugwell, P. Measurement of Patient Outcome. *British Journal of Rheumatology*. 1983; 22(Supplement):86-89.
42. Tugwell P, Bombardier C. "Practical Issues in Clinical Trials as Applied to Current State of the Art in Rheumatology Trials". *British Journal of Rheumatology*. 1983; 22(Supplement):9-13.
43. Department of Clinical Epidemiology and Biostatistics. *Clinical Epidemiology Rounds: Interpretation of Diagnostic Data, 1. How to do it with Pictures*. Canadian Medical Association Journal. 1983; 129:429-432.
44. Bombardier C, Tugwell P. Measuring Disability: Guidelines for Rheumatology Studies. *Journal of Rheumatology*. 1983; 10(Supplement):68-73.

45. Tugwell P, Bombardier C. Methodologic Issues in International Rheumatologic Clinical Epidemiology. *Journal of Rheumatology*. 1983; 10(Supplement):65-67.
46. Hunter DJ, Enkin MW, Sargeant EJ, Wilkinson J, Tugwell P. The Outcome of Prolonged Labor as Defined by Partography and the Use of Oxytocin: A Descriptive Study. *American Journal Obstetrics Gynecology*. 1983; 145(2):189-192.
47. Haynes RB, Sackett D, Tugwell P. Problems in the Handling of Clinical and Research Evidence by Medical Practitioners. *Archives of Internal Medicine*. 1983; 143:1971-1975.
48. Tugwell P. Hoe Moeten Medische Tijdschriften Worden Gelezen? III. Het beoornden van het klinische beloop en de prognose van een ziekte. *Ned Tijdschr Geneesk*. 1983; 52:2367-71.
49. Department of Clinical Epidemiology and Biostatistics. Clinical Epidemiology Rounds: Interpretation of Diagnostic Data: 2. How to do it with a simple table (Part A). *Canadian Medical Association Journal*. 1983; 129:559-564.
50. Department of Clinical Epidemiology and Biostatistics. Clinical Epidemiology Rounds: Interpretation of Diagnostic Data: 3. How to do it with a simple table (Part B). *Canadian Medical Association Journal*. 1983; 129:705-710.
51. Department of Clinical Epidemiology and Biostatistics. Clinical Epidemiology Rounds: Interpretation of Diagnostic Data: 4. How to do it with a more complex table. *Canadian Medical Association Journal*. 1983; 129:832-835.
52. Department of Clinical Epidemiology and Biostatistics. Clinical Epidemiology Rounds: Interpretation of Diagnostic Data: 5. How to do it with simple maths. *Canadian Medical Association Journal*. 1983; 129:947-954.
53. Department of Clinical Epidemiology and Biostatistics. Clinical Epidemiology Rounds: Interpretation of Diagnostic Data: 6. How to do it with more complex maths. *Canadian Medical Association Journal*. 1983; 129:1093-1099.
54. Chambers LW, Mohide EA, Pill M, Bayne RBA, Caulfield P, Rudnick V, Tugwell P, Baptiste S, Magenheimer M, King M. A Self Monitoring Method of Resident Care Quality Assurance in Long Term Care Facilities. *Gerontologist*. 1983; pp.23:89.
55. Davis D, Haynes RB, Chambers L, Neufeld VR, McKibbon A, Dok C, Manganelli B, Tugwell P. Continuing Medical Education: Annotated Bibliography *Annals of Royal College of Physicians and Surgeons of Canada*. 1983; 16:85-90.
56. Department of Clinical Epidemiology and Biostatistics: Clinical Epidemiology Rounds: How to Read Clinical Journals: VI. To Learn about the Quality of Clinical Care. *Canadian Medical Association Journal*. 1984; 130:377-381.
57. Viviani G, Budgell L, Dok C, Tugwell P. Assessment of the Accuracy of the Scoliosis School Screening Examination. *The American Journal of Public Health*. 1984; 74(5):497-498.
58. Bensen W, Moore N, Tugwell P, D'Souza M, Singal D. HLA Antigens and Toxic Reactions to Sodium Aurothiomalate in Patients with Rheumatoid Arthritis. *Journal of Rheumatology*. 1984; 11(3):358-361
59. Haynes RB, Davis DA, McKibbon A, Tugwell P. A Critical Appraisal of the Efficacy of Continuing Medical Education. *Journal of the American Medical Association*. 1984; 251(1):61-64.

60. Tugwell P, Hart L, Kraag G, Park A, Dok C, Bianchi F, Goldsmith C, Buchanan W. A Controlled Trial of Clinical Utility of Serum Salicylate Monitoring in Rheumatoid Arthritis. *Journal of Rheumatology*. 1984; 11(4):457-461.
61. Chambers LW, Mohide EA, Bayne R, Caulfield P, Rudnick V, Baptiste S, Magenheimer M, Tugwell P, King M, Pill M. A Self-Monitoring Method of Resident Care Quality Assurance in Long Term Care Facilities. *The Canadian Journal on Aging*. 1984; 2(3):137-151.
62. Belcon MC, Haynes RB, Tugwell P. A critical review of compliance studies in Rheumatoid Arthritis. *Arthritis & Rheumatism*. 1984; 27:1227-1233.
63. Tugwell P, Bennett K, Sackett DL, Haynes RB. Relative Risks, Benefits, and Costs of Intervention. Chapter in: *Tropical and Geographical Medicine*. Warren KS, Mahmoud AAF (Eds.). McGraw Hill, 1984; pp.1097-1113.
64. Davis D, Haynes RB, Chambers L, Neufeld VR, McKibbin A, Tugwell P. The Impact of CME: A Methodological Review of the Continuing Medical Education Literature. *Evaluation and the Health Professions*. McMaster University Press. 1984; 7(3):251 -283.
65. Tugwell P, Manganelli B. The Clinical Audit Cycle. Chapter in: *Quality Assurance and the 1983 Standards*. Ontario Hospital Association. 1984.
66. Baynham R., Krilyk J., Manganelli E.J. and Tugwell P.: *Problem Based Clinical Audit Handbook*. Chedoke-McMaster Hospitals. 1984.
67. Tugwell P, Dok C. Medical Record Review. Chapter in: *Assessment of Clinical Competence*. Neufeld V, Norman GR (Eds.). Springer Publishing Co., 1984; pp.142-182.
68. Bellamy N, Grace E, Hanna B, Grant E, Tugwell P, Buchanan WW. Clinical Evaluation of Two Strategies for Improving Patient Recall of Prior Drug Therapy. *British Journal of Clinical Pharmacology*. 1984; 17:769-772.
69. Haynes RB, Sackett DL, Tugwell P. Assessment of the Use of Diagnostic Tests. Chapter in: *Assessing Clinical Competence*. Neufeld V, Norman GR (Eds.). Springer Publishing Co., 1984; Vol. 7, pp.275-294.
70. Buchanan WW, Gopal DN, Ghista DN, Grace EM, Tugwell P. Rheumatoid Hand Weakness Characterizing Indices and Clinical Data Acquisition. *Eng. Med*. 1984; 13(3):115-120.
71. Buchanan WW, Tugwell P. Clinical Evaluation in Rheumatic Diseases. In: 10th Edition of *Arthritis and Allied Diseases*. McCarty DJ (Ed.). Lea & Febiger Publishers. 1985; Vol. 7, pp.156-170.
72. Hertzman C, Tugwell P, Sackett D, Rainbow A, Kahana L, Zylak C. Comparison of Two Hospital Tuberculosis Surveillance Programs: Risks and Benefits. *Journal of Canadian Public Health Association*. 1985; 76:237-243.
73. Belcon MC, Rooney PJ, Tugwell P. Aspirin and Gastrointestinal Hemorrhage: A Methodologic Assessment. *Journal of Chronic Disease*. 1985; 38(1):101-111.
74. Tugwell P, Bennett K, Sackett D, Haynes B. The Measurement Iterative Loop: A Framework for the Critical Appraisal of Need, Benefits and Costs of Health Interventions (and its application to hypertension and joint replacement). *Journal of Chronic Disease*. 1985; 38(4):339-351.
75. Bombardier C, Tugwell P. Controversies in the Analysis of Long Term Clinical Trials of Slow Acting Drugs. *Journal of Rheumatology*. 1985; 12(3):403-405.

76. Hart LE, Tugwell P, Buchanan WW, Norman GR, Grace EM, Southwell D. Grading of Tenderness as a Source of Interrater Error in the Ritchie Articular Index. *Journal of Rheumatology*. 1985; 12(4):716-717.
77. Norman GE, Tugwell P, Feightner JW, Muzzin LJ, Jacoby LL. Knowledge and Clinical Problem Solving. *Medical Education*. 1985; 19(5):344-356.
78. Bennett K, Feeny D, Guyatt G, Tugwell P, Drummond M. Guidelines for Health Technology Assessment: The Efficacy, Effectiveness and Efficiency of Neonatal Intensive Care. *International Journal of Technology Assessment in Health Care*. 1985; 1:4.
79. Tugwell P. Quality of Life Scales - Are they Measurable? I.L.A.R. Proceedings. 1985; Elsevier Press.
80. Tugwell P. Patient Preference Scales. *Agents Actions*. 1985; 17(Supplement):29-31.
81. Guyatt G, Bombardier C, Tugwell P. Measuring Disease-Specific Quality of Life in Clinical Trials. *Canadian Medical Association Journal*. 1986; 134(8):889-895.
82. Guyatt G, Drummond M, Feeny D, Tugwell P, Stoddart G, Haynes RB, Bennett K, Labelle R. Guidelines for the Clinical and Economic Evaluation of Health Care Technologies. Monograph. Institute of Research and Public Policy. *Social Science Medicine*. 1986; 22(4):393-408.
83. Guyatt G, Tugwell P, Feeny D, Drummond M, Haynes RB. The Role of Before-After Studies of Therapeutic Impact in the Evaluation of Diagnostic Technologies. *Journal of Chronic Disease*. 1986; 9(4):295-304.
84. Guyatt G, Tugwell P, Feeny D, Haynes R, Drummond M. A Framework for Clinical Evaluation of Diagnostic Technologies. *Canadian Medical Association Journal*. 1986; 134(6):587-94.
85. Manganelli B, Tugwell P. Current Concepts in Continuing Medical Education. Educational Audit. *Annals of Royal College of Physicians and Surgeons*. 1986; 19(3):187-189.
86. Tugwell P, Manganelli B. The Clinical Audit Cycle. Originally published in *Quality Assurance and the 1983 Standards* (Toronto, Ontario: Ontario Hospital Association, 1984). *Australian Clinical Review*. 1986; 6(21):100-106.
87. Bennett K, Tugwell P. Iterative Loop Gives Framework for Assessing Technology. *Dimensions in Health Service*. 1986; 63(8):68-71.
88. Tugwell P. Postgraduate Training Around the World. *Postgraduate Training in Canada*. *Postgraduate Medical Journal*. 1987; 63:707-709.
89. Tugwell P, Bombardier C, Buchanan WW, Goldsmith C, Grace E. The MACTAR Patient Preference Questionnaire - An Individualized Functional Priority Approach for Assessing Improvement in Physical Disability in Clinical Trials in Rheumatoid Arthritis. *Journal of Rheumatology*. 1987; 14(3):446-561.
90. Tugwell P, Bennett K, Gent M. Methotrexate in Rheumatoid Arthritis: Indications, Contraindications, Efficacy and Safety. *Annals of Internal Medicine*. 1987; 107:358-366.
91. Tugwell P, Bombardier C, Gent M, Bennett K, Ludwin D, Grace E, Buchanan W, Murphy G. Low Dose Cyclosporine in Rheumatoid Arthritis: A Pilot Study. *Journal of Rheumatology*. 1987; 14(6):1108-1114.
92. Roberts J, Tugwell P. Comparison of Questionnaires Determining Patient Satisfaction with Medical Care. *Health Services Research*. 1987; 22(5):637-654.

93. Bombardier C, Tugwell P. Methodologic Considerations in Functional Assessment. *Journal of Rheumatology*. 1987; 14(Supplement 15):6-10.
94. Bennett KJ, Sackett DL, Haynes RB, Neufeld VR, Tugwell P, Roberts R. A Controlled Trial of Teaching Critical Appraisal of the Clinical Literature to Medical Students. *Journal of the American Medical Association*. 1987; 257(18):2451-4.
95. Norman GR, Tugwell P, Feightner JW. A Comparison of Resident Performance on Real and Simulated Patients. In: *How to Evaluate Residents*. Lloyd JS, Langsley DG (Eds.). American Board of Medical Specialties, Chicago, 1987.
96. Klinkhoff A, Bellamy N, Bombardier C, Carette S, Chalmers A, Esdaile J, Goldsmith C, Tugwell P, Smythe H, Buchanan W. An Experiment in Reducing Interobserver Variability of the Examination for Joint Tenderness. *Journal of Rheumatology*. 1988; 15:492-494.
97. Grace E, Gerecz E, Kassam Y, Buchanan H, Buchanan W, Tugwell P. 50-foot Walking time: A Critical Assessment of an Outcome Measure in Clinical Therapeutic Trials of Antirheumatic Drugs. *British Journal of Rheumatology*. 1988; 27(5):372-374.
98. Bennett K, Neufeld V, Tugwell P. A Global Perspective: Opportunities for Internists to Contribute to and Learn from International Health Collaboration. *Journal of General Internal Medicine*. 1988; 3(2):171-176.
99. Van der Linden S, Asim Khan M, Rentsch H, Gerber N, Cats A, Valkenburg H, Tugwell P. Chest Pain Without Radiographic Sacroiliitis in Relatives of Patients with Ankylosing Spondylitis. *Journal of Rheumatology*. 1988; 15(5):725-727.
100. Ludwin D, Bennett K, Grace E, Buchanan W, Bensen W, Bombardier C, Tugwell P. Nephrotoxicity in Patients with Rheumatoid Arthritis Treated with Cyclosporine. *Transplant Proceedings*. 1988; 3(Supplement 4):367-370.
101. Mohide EA, Mohide A, Tugwell P, Caulfield P, Chambers C, Dunnett C, Baptiste S, Bayne JR, Patterson C, Rudnick V, Pill M. A Randomized Trial of Quality Assurance in Nursing Homes. *Medical Care*. 1988; 26(6):554-565.
102. Van der Linden S, Tugwell P. Pitfalls in Assessment of Prognosis. Weak Study Designs Are Liable to Bias. *The Journal of Rheumatology*. 1988; 15(5):725-727.
103. Mohide EA, Royle J, Porterfield P, Montenuero M, Scott J, Tugwell P. Assessing the Quality of Cancer Pain Management. *The Journal of Palliative Care*. 1988; 4(3):9-15.
104. Schrieber L, McCredie, Tugwell P, Brooks PM. An Evaluation of the Role of Laboratory Investigations in Establishing a Diagnosis of Central Nervous System Lupus. *British Journal of Rheumatology*. 1988; 7(2):138-142.
105. Clark P, Tugwell P, Bennett K, Bombardier C. Meta-Analysis of Injectable Gold in Rheumatoid Arthritis. *Journal of Rheumatology*. 1989; 16(4):442-447.

106. Grace E, Tugwell P. Editorial on Rheumatoid Arthritis. *Triangle*, 1989; 28(1/2):1-4.
107. Tugwell P, Bennett K, Bell M, Gent M. Methotrexate in Rheumatoid Arthritis - Feedback on American College Guidelines. *Annals of Internal Medicine*. 1989; 110(8):581-583.
108. Hart LE, Tugwell P. Difficult Decisions: The Use of Disease Modifying Antirheumatic Drugs in the Management of Rheumatoid Arthritis. *Postgraduate Medical Journal*. 1989; 65:905-912.
109. Laupacis A, Rorabeck C, Bourne R, Feeny D, Tugwell P, Sim D. Randomized Trials in Orthopaedics: Why, How, and When? *Journal of Bone Joint Surgery (Am)*. 1989; 71(4):535-543.
110. MacDonald P, Chong J, Chongtrakul P, Neufeld V, Tugwell P, Chambers L, Pickering R, Oates M. Setting Educational Priorities for Learning the Concepts of Population Health. *Medical Education*. 1989; 23(5):429-439.
111. Esdaile JM, Chalmers TC, Felson DT, Tugwell P. Symposium: Clinical Applications of Meta-Analysis. Clinical Research Symposium supported by the Canadian Rheumatism Association, American Rheumatism Association (northeast region), Canadian Society of Clinical Investigation, Royal College of Physicians and Surgeons of Canada. *Annals RCPSC*. 1989; 22(6):453-454.
112. Wolfe F, Smythe H, Muhammad B, Bennett R, Bombardier C, Goldenberg D, Tugwell P et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia - Report of the Multicenter Criteria Committee. *Arthritis & Rheumatism*. 1990; 33(2):160-172.
113. Strom B, Tugwell P. Pharmacoepidemiology: Current Status, Prospects and Problems. *Annals of Internal Medicine*. 1990; 113(3):179-181.
114. Tugwell P, Bombardier C, Buchanan WW, Goldsmith C, Grace E, Bennett K. Methotrexate in Rheumatoid Arthritis. Impact on Quality of Life Assessed by Traditional Standard-Item and Individualized Patient Preference Health Status Questionnaires. *Archives of Internal Medicine*. 1990; 150(1):59-62.
115. Tugwell P, Bombardier C, Gent M, Bennett K, Bensen W, Carette S. A Multicentre, Double-Blind, Randomized Trial of Low-Dose Cyclosporine and Placebo Therapy in Patients with Rheumatoid Arthritis. *The Lancet*. 1990; 335:1051-1055.
116. Chambers L, Tugwell P, Goldsmith C, Caulfield P. The Health Status of Elderly Home Care Patients Recently Discharged from Hospital in an Ontario Community. *Canadian Journal on Aging*. 1990; 9(4):327-347.
117. Bell MJ, Bombardier C, Tugwell P. Measurement of Functional Status, Quality of Life, and Utility in Rheumatoid Arthritis. *Arthritis & Rheumatism*. 1990; 33(4):591-601.
118. Van der Linden S, Ferraz M, Tugwell P. Clinical and Functional Assessment of Ankylosing Spondylitis. *Spine*. 1990; 4(3):583-593.
119. Bensen WG, Bensen W, Adachi JD, Tugwell P. Remodelling the Pyramid: The Therapeutic Target of RA. *Journal of Rheumatology*. 1990; 17(8):987-989.
120. Ferraz MB, Quaresma MR, Aquino LRL, Tugwell P, Goldsmith CH. Reliability of Pain Scales in the Assessment of Literate and Illiterate Patients with RA. *Journal of Rheumatology*. 1990; 17(8):1022-1024.
121. Gercz-Simon E, Soper WY, Kean WF, Rooney PJ, Tugwell P, Buchanan WW. A Controlled Comparison of Piroxicam and Diclofenac in Patients with Osteoarthritis. *Clin Rheumatol*. 1990; 9(2):229-234.

122. Singer J, Denburg JA et al. Diagnostic Criteria for Neuropsychiatric Systemic Lupus Erythematosus: The Results of a Consensus Meeting (Workshop Report). *Journal of Rheumatology*. 1990; 17(10):1397-1402.
123. Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-Analysis of Sulfasalazine in Ankylosing Spondylitis. *Journal of Rheumatology*. 1990; 17(11):1482-1486.
124. Bennett K, Tugwell P, Sackett D, Haynes B. Clinical, Biological, and Epidemiological Considerations in the Approach to Tropical Medicine: Relative Risks, Benefits, and Costs of Intervention. In: *Tropical and Geographical Medicine*, 2nd Ed. (1st Ed. 1984). Edited by S.Y. Kenneth and A.A.F. Mahmoud, McGraw-Hill, Inc., 1990, Chapter 27, 205-228.
125. Tugwell P. Overview of Cyclosporin in Rheumatoid Arthritis. In: *Autoimmunity, Rheumatoid Arthritis and Cyclosporin A*. Mizushima Y, Amor B (Eds.). Parthenon Publishing Group Ltd. 1991; 83-93.
126. Helewa A, Goldsmith CH, Lee P, Bombardier C, Hanes B, Smythe HA, Tugwell P. Effects of Occupational Therapy Home Service on Patients with Rheumatoid Arthritis. *The Lancet*. 1991; 337:1453-1456.
127. Riedemann JP, Cardiel MH, Tugwell P. Update: Slow Acting Anti-Rheumatic Drugs in Rheumatoid Arthritis. *Comprehensive Therapy (Musculoskeletal Disorders Issue)*. 1991; 17(6):61-68.
128. Tugwell P. Rheumatology Leading Article: Cyclosporine in the Treatment of Rheumatoid Arthritis. Clinical and Experimental Perspectives in Sandimmune Therapy. 1991; 1(2):44-49.
129. Bennett K, Torrance G, Tugwell P. Methodologic Challenges in the Development of Utility Measures of Health-Related Quality of Life in Rheumatoid Arthritis. *Controlled Clinical Trials*. 1991; 12:118S-128S.
130. Tugwell P, Bombardier C, Bell M, Bennett K, Bensen W, Grace E, Hart L, Goldsmith C. Current Quality-of-Life Research Challenges in Arthritis Relevant to the Issue of Clinical Significance. *Controlled Clinical Trials*. 1991; 12:217S-225S.
131. Halstead SB, Tugwell P, Bennett K. The International Clinical Epidemiology Network (INCLEN): A Progress Report. *Journal of Clinical Epidemiology*. 1991; 44(6):579-589.
132. Lawrence VA, Tugwell P, Gafni A, Kosuwon W, Spitzer WO. Acute Low Back Pain and Economics of Therapy: The Iterative Loop Approach. *Journal of Clinical Epidemiology*. 1992; 45:301-311.
133. Reynolds DL, Chambers LW, Badley EM, Bennett KJ, Goldsmith CH, Jamieson E, Torrance GW, Tugwell P. Physical Disability Among Canadians Reporting Musculoskeletal Diseases. *Journal of Rheumatology*. 1992; 19(7):1020-1030.
134. Laupacis A, Feeny D, Detsky AS, Tugwell P. How Attractive Does a New Technology Have to Be to Warrant Adoption and Utilization? Tentative Guidelines for Using Clinical and Economic Evaluations (Special Article). *Canadian Medical Association Journal*. 1992; 146(4):473-.
135. Tugwell P. Cyclosporin in the Treatment of Rheumatoid Arthritis. *Journal of Autoimmunity*. 1992; 5(SA):231-240.
136. Pryse-Phillips W, Findlay H, Tugwell P, Edmeads J, Murray TJ, Nelson RF. A Canadian Population Survey on the Clinical, Epidemiologic and Societal Impact of Migraine and Tension-Type Headache. *Canadian Journal of Neurological Sciences*. 1992; 19(3):333-339.
137. Tugwell P. Cyclosporine in Rheumatoid Arthritis: Documented Efficacy and Safety. *Seminars in Arthritis and Rheumatism*. 1992; 21(6S3):30-38.

138. Bombardier C, Buchbinder R, Tugwell P. Efficacy of Cyclosporin A in Rheumatoid Arthritis: Long-term Follow-up Data and the Effect on Quality of Life. *Scandinavian Journal of Rheumatology*. 1992; 21(S95):29-33.
139. Boers M, Bensen WG, Ludwin D, Goldsmith CH, Tugwell P. Cyclosporine Nephrotoxicity in Rheumatoid Arthritis: No Effect of Short Term Misoprostol Treatment. *Journal of Rheumatology*. 1992; 19(4):534-537.
140. Tugwell P, Chambers L, Torrance G, Reynolds D, Wolfson M, Bennett K, Badley E, Jamieson E, Stock S for the POHEM Workshop Group. The Population Health Impact of Arthritis Workshop Report. *Journal of Rheumatology*. 1993; 20(6):1048-1051.
141. Panayi GS, Tugwell P. An International Consensus Report: The Use of Cyclosporin A in Rheumatoid Arthritis. *British Journal of Rheumatology*. 1993; 32(S1):1-3.
142. Wells G, Tugwell P. Cyclosporin A in Rheumatoid Arthritis: Overview and Efficacy. *British Journal of Rheumatology*. 1993; 32(S1):51-56.
143. Laupacis A, Bourne R, Rorabeck C, Feeny D, Wong C, Tugwell P, Leslie K, Bullas R. The Effect of Elective Total Hip Replacement Upon Health-Related Quality of Life. *The Journal of Bone and Joint Surgery*. 1993; 75(11):1619-1626.
144. Tugwell P, Goldsmith C. Rheumatology: Management of rheumatic diseases. Science of rheumatic disease management. Section 8: Chapter 2.1-8. Klippel J.H. and Dieppe P., Eds. 1994.
145. Neufeld V, Bergevin Y, Tugwell P. The Role of Academic Health Sciences Centres in International Health. *Canadian Medical Association Journal*. 1993; 148(9):1546-1549.
146. Riedemann PJ, Bersinic S, Cuddy L, Torrance GW, Tugwell P. A Study to Determine the Efficacy and Safety of Tenoxicam Versus Piroxicam, Diclofenac and Indomethacin in Patients with Osteoarthritis: A Meta-analysis. *Journal of Rheumatology*. 1993; 20(12):2095-2103.
147. Tugwell P, Boers M for the OMERACT Committee. Proceedings of the OMERACT Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials, Maastricht, Netherlands, April 29-May 3, 1992. *Journal of Rheumatology*. 1993; 20(3):527-591.
148. Wells G, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA. Minimum Important Difference Between Patients with RA: The Patient's Perspective. *Journal of Rheumatology*. 1993; 20(3):557-560.
149. Tugwell P, Boers M for the OMERACT Committee. Developing Consensus on Preliminary Core Efficacy Endpoints for RA Clinical Trials. *Journal of Rheumatology*. 1993; 20(3):555-556.
150. Goldsmith CH, Boers M, Bombardier C, Tugwell P for the OMERACT Committee. Criteria for Clinically Important Changes in Outcomes: Development, Scoring and Evaluation of RA Patient and Trial Profiles. *Journal of Rheumatology*. 1993; 20(3):561-565.
151. Boers M, Tugwell P. The Validity of Pooled Outcome Measures (Indices) in RA Clinical Trials. *Journal of Rheumatology*. 1993; 20(3):568-574.
152. Reynolds DL, Torrance GW, Badley EM, Bennett KJ, Chambers LW, Goldsmith CH, Jamieson E, Tugwell P, Wolfson MC. Modeling the Population Health Impact of Musculoskeletal Diseases: Arthritis. *Journal of Rheumatology*. 1993; 20(6):1037-1047.
153. Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, Orozco JA. A Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in the Treatment of Rheumatoid Arthritis: A Reassessment of the Drug. *Annals of Internal Medicine*. 1993; 119(11):1067-1071.

154. Feutren G, Mihatsch MJ, Hovig T, Lemoine R, Alexopoulou I, Forre O, Miescher P, Favre H, Ludwin D, Tugwell P, Bjerkhoel N, von Graffenreid B. Renal Morphology After Cyclosporin A Therapy in Rheumatoid Arthritis Patients: International Kidney Biopsy Registry of Cyclosporin (Sandimmun) in Autoimmune Diseases. *British Journal of Rheumatology*. 1993; 32(S1):65-71. (RM-1598).
155. Oxman AD, Sackett DL, Guyatt GH for the Evidence-Based Medicine Working Group. Users' Guide to the Medical Literature: I. How to Get Started. *The Journal of the American Medical Association*. 1993; 270(17):2093-2095.
156. Guyatt GH, Sackett DL, Cook DJ for the Evidence-Based Medicine Working Group. Users' Guide to the Medical Literature: II. How to Use an Article About Therapy or Prevention, A. Are the Results of the Study Valid? *The Journal of the American Medical Association*. 1993; 270(21):2598-2601.
157. Laupacis A, Feeny D, Detsky AS, Tugwell P. Tentative Guidelines for Using Clinical and Economic Evaluations Revisited [comment]. *Canadian Medical Association Journal*. 1993; 148(6):927-929.
158. Felson D, Anderson J, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith CH, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams J, Wolfe F. American College of Rheumatology Preliminary Core Set of Disease Activity Measures for Use in Rheumatoid Arthritis Clinical Trials. *Arthritis and Rheumatism*. 1993; 36(6):729-740.
159. Tugwell P. Workshop C: Measuring and Reporting Outcomes. *Proceedings: Canadian Collaborative Workshop on Pharmacoeconomics*, June 21-22, 1993. Schubert F., Ed., Excerpta Medica, Inc., Princeton, N.J.; 1993: 38-42.
160. Edmeads J, Findlay H, Tugwell P. Pryse-phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on lifestyle, consulting behaviour, and medication use: A Canadian population survey. *Canadian Journal of Neurological Sciences*. 1993; 20(2):131-7.
161. Boers M, Tugwell P. OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction (Review). *Journal of Rheumatology*. 1993; 20(3):552-4.
162. Ludwin D, Alexopoulou I, Esdaile JM, Tugwell P for the Canadian Multicentre Rheumatology Group. Renal Biopsies from Patients with Rheumatoid Arthritis and Apparently Normal Renal Function After Therapy with Cyclosporine. *American Journal of Kidney Diseases*. 1994; 23(2):260-265.
163. Laupacis A, Bourne RB, Rorabeck CH, Feeny D, Wong C, Tugwell P, Leslie K, Bullas R. Costs of Elective Total Hip Arthroplasty During the First Year. Cemented Versus Non-Cemented. *Journal of Arthroplasty*. 1994; 9(5):481-487.
164. Guyatt GH, Sackett DL, Cook DJ for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature: II. How to Use an Article About Therapy or Prevention, B. What Were the Results and Will They Help Me in Caring for My Patients? *The Journal of the American Medical Association*. 1994; 271(1):59-63.
165. Tugwell P. Selecting Outcome Measures for Biologic Agents. *Proceedings: Early Decisions in DMARD Development III "Biologic Agents in Autoimmune Diseases"*, March 4-5, 1994. Published by the Arthritis Foundation, May 1994: 124-128.
166. Tugwell P, Boers M. Long-Acting Drug Combinations in Rheumatoid Arthritis - Updated Overview. In: *Rheumatoid Arthritis - Pathogenesis, Assessment, Outcome, and Treatment*, Wolfe F. and Pincus T., Eds. Marcel Dekker, Inc., New York, USA; 1994: chapter 16, 357-371.

167. Laupacis A, Wells G, Richardson WS, Tugwell P. Users' Guides to the Medical Literature. V. How to Use an Article About Prognosis. Evidence-Based Medicine Working Group. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. *The Journal of the American Medical Association*. 1994; 272(3):234-237.
168. Rorabeck CH, Bourne RB, Laupacis A, Feeny D et al. A Double-blind Study of 250 Cases Comparing Cemented with Cementless Total Hip Arthroplasty. Cost-effectiveness and its Impact on Health-related Quality of Life. *Clinical Orthopaedics*. 1994; 298:156-164.
169. Bensen W, Tugwell P, Gent M, Ross H, Grace E, Roberts R, Ludwin D. Combination Therapy of Cyclosporin with Methotrexate and Gold in Rheumatoid Arthritis (2 Pilot Studies). *Journal of Rheumatology*. 1994; 21(11):2034-2038.
170. Jaeschke R, Guyatt G, Sackett DL for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature. III. How to Use an Article About a Diagnostic Test. A. Are the Results of the Study Valid? *The Journal of the American Medical Association*. 1994; 271(5):389-391.
171. Jaeschke R, Guyatt G, Sackett DL for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature. III. How to Use an Article About a Diagnostic Test. B. What Are the Results and Will They Help Me in Caring for My Patients. *The Journal of the American Medical Association*. 1994; 271(9):703-707.
172. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V for the Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature. IV. How to Use an Article About Harm. *The Journal of the American Medical Association*. 1994; 271(20):1615-1619.
173. Tugwell P, Boers M, Baker P, Wells G, Snider J. Endpoints in Rheumatoid Arthritis. *The Journal of Rheumatology*. 1994; 21(10):2-8.
174. Panayi GS, Tugwell P. Conclusions of an International Review: The Use of Cyclosporin A in Rheumatoid Arthritis. *British Journal of Rheumatology*. 1994; 33:967-969.
175. Tugwell P, Baker P. DC-ART: Improvement and Sustained Improvement in Function. *The Journal of Rheumatology*. 1994; 21(S41):23-24.
176. Tugwell P. Comment: Are There Special Considerations Relevant to Trials of Biologic Agents? *The Journal of Rheumatology*. 1994; 21(S41):45-46.
177. Boers M, Tugwell P, Felson DT, van Riel PLCM, Kirwan JR, Edmonds JP, Smolen JS, Khaltsev N, Muirden KD. WHO and ILAR Core Endpoints for Symptom Modifying Antirheumatic Drugs in Rheumatoid Arthritis Clinical Trials. *The Journal of Rheumatology*, 1994; 21(S41):86-89.
178. Moher D for the Standards of Reporting Trials Group. A Proposal for Structured Reporting of Randomized Controlled Trials. *Journal of the American Medical Association*. 1994; 272:1926-1931.
179. Bourne RB, Rorabeck CH, Laupacis A, Feeny D, Wong C, Tugwell P, Leslie K, Bullas R. A randomized clinical trial comparing cemented to cementless hip replacement in 250 osteoarthritic patients: the impact on health-related quality of life and cost effectiveness. *Iowa Orthopaedic Journal*. 1994; 14:108-14.
180. Bourne RB, Rorabeck CH, Laupacis A, Feeny D, Tugwell P, Wong C, Bullas R. Total Hip Replacement: The case for non-cemented femoral fixation because of age. *Canadian Journal of Surgery*. 1995; 38(1):S61-S66.
181. Podrebarac T, Tugwell P. The Newer Second-Line Agents: Cyclosporin. In: *Therapy of Systemic Rheumatic Disorders*, van de Putte L., Furst D., van Riel P. and Williams H.J., Eds. Marcel Dekker, Inc., New York, USA; 1995.

182. Tugwell P, Baker P. Guidelines for the use of cyclosporine in rheumatoid arthritis. *Clinical Therapy*. 1995; 14 (Suppl) 2:37-41.
183. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr., Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis & Rheumatism*. 1995; 38:727-735.
184. Lassere M, Wells G, Tugwell P, Edmonds J. Percentile Curve Reference Charts of Physical Function: Rheumatoid Arthritis Population. *The Journal of Rheumatology*. 1995; 22(7):1241-1246.
185. Felson DT for the ACR Committee on Outcome Measures in RA Trials. American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis. *Arthritis and Rheumatism*. 1995; 38(6):727-735.
186. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists. *Controlled Clinical Trials*. 1995; 16:62-73.
187. Tugwell P, Pincus T, Yocum D, Stein M, Kraag G, McKendry R, Tesser J, Baker P, Wells G. Combination Therapy with cyclosporin and methotrexate in severe RA. *New England Journal of Medicine*. 1995; 333(3):137-141.
188. Boers M, Brooks PM, Tugwell P. OMERACT II Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Introduction: OMERACT: State of the "Act". *Journal of Rheumatology*. 1995; 22(5):979-981.
189. Goldsmith CH, Duku E, Brooks PM, Boers M, Tugwell P, Baker P for the OMERACT II Committee. Interactive Conference Voting. *Journal of Rheumatology*. 1995; 22(7):1420-1430.
190. Tugwell P, Boers M, Brooks PM. OMERACT II Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Conclusion. *Journal of Rheumatology*. 1995; 22(7):1431-1432.
191. Bergevin Y, Tugwell P. Introduction: Needs-Based Technology Assessment: Who Can Afford Not to Use It? *International Journal of Technology Assessment in Health Care*. 1995; 11(4):647-649.
192. Tugwell P, Sitthi-Amorn C, O'Connor A, Hatcher-Roberts J, Bergevin Y, Wolfson M. Technology Assessment: Old, New and Needs-Based. *International Journal of Technology Assessment in Health Care*. 1995; 11(4):650-662.
193. Darmawan J, Bosi-Ferraz M, Muirden KD, Tugwell P. Case Study: World Health Organization - International League of Associations for Rheumatology's Community-Oriented Program for the Control of Rheumatic Diseases (WHO-ILAR COPCORD) in Indonesia and Brazil. *International Journal of Technology Assessment in Health Care*. 1995; 11(4):700-708.
194. Tugwell P. International Consensus Recommendations on Cyclosporin Use in Rheumatoid Arthritis. *Drugs*. 1995; 50(S1):48-56.
195. Buchbinder R., Bombardier C., Yeung M., Tugwell P. Which Outcome Measures Should Be Used in Rheumatoid Arthritis Clinical Trials? Clinical and Quality-of-Life Measures' Responsiveness to Treatment in a Randomized Controlled Trial. *Arthritis and Rheumatism*. 1995; 38(11): 1568-1580.
196. Boers M, van Riel RL, Felson DT, Tugwell P. Assessing the Activity of Rheumatoid Arthritis. *Baillieres Clinical Rheumatology*, 1995; 9(2):305-317.

197. Laupacis A, Rorabeck C, Bourne R, Rankin R, Vellet AD, Feeny D, Bullas R, Wong C, Tugwell P. A Randomized Clinical Trial Comparing Cemented to Cementless Total Hip Replacement in 250 Osteoarthritic Patients: The Impact on Health-Related Quality of Life and Cost-Effectiveness. *Iowa Orthopedic Journal*, 1994; 14:108-114.
198. Anis AH, Tugwell P, Torrance GW, Wells GA, Stewart D, Yetisir L. A Cost-Effectiveness Analysis of Cyclosporine in Rheumatoid Arthritis. *Journal of Rheumatology*. 1996;Vol 23(4); 609-616.
199. Tugwell P and Boers M. Clinical Epidemiology of the Rheumatic Diseases. In: *Textbook of Rheumatology*, 5th Edition, Kelley WN, Harris ED, Jr, Ruddy S, Sledge CB, Editors. W.B. Saunders Company, Philadelphia; 1995:343-352.
200. Ortiz Z, Tugwell P. Raised ESR in polymyalgia rheumatica no longer a sine qua non? *The Lancet* 1996; 348: 4-5.
201. Laupacis A, Rorabeck C, Bourne R, Tugwell P, Bullas R, Rankin R, Vellet AD, Feeny D, Wong C. The Frequency of Venous Thrombosis in Cemented and Non-Cemented Hip Arthroplasty. *The Journal of Bone and Joint Surgery* 1996 78-B(2):210-212.
202. Michaud G, McGowan JL, van der Jagt R, Dugan AK, Tugwell P. The introduction of evidence-based medicine as a component of daily practice. *Bulletin of the Medical Library Association* 1996; 84(4):478-481.
203. Rodriguez F, Krayenbuhl JC, Harrison WB, Forre O, Dijkmans BAC, Tugwell P, Miescher PA, Mihatsch MJ. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. *Arthritis & Rheumatism* 1996 39(9):1491-1498.
204. Tugwell P, Ortiz Z, Griffith B. Combination therapy of severe rheumatoid arthritis at an early stage of the disease. *Schweizerische Medizinische Wochenschrift (Supp)* 1996; 80:20S-21S.
205. Stock SR, Cole DC, Tugwell P, Streiner D. Review of applicability of existing functional status measures to the study of workers with musculoskeletal disorders of the neck and upper limb. (Review). *American Journal of Industrial Medicine* 1996; 29(6):679-688.
206. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, SEbaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis - a 3-year followup. *Journal of Rheumatology* 1996; 23(6):995-1000.
207. Baker PRA, Groh JD, Kraag GR, Tugwell P, Wells GA, Boisvert D. Impact of patient with patient interaction on perceived rheumatoid arthritis overall disease status. *Scandinavian Journal of Rheumatology*. 1996; 25(4);207-212.
208. Moher D, Jadad A, Tugwell P. Assessing the quality of clinical trials: current issues and future directions. *International Journal of Technology Assessment in Health Care* 1996;12(2):195-208.
209. Hébert PC, Tugwell P. How to Evaluate the Medical Literature: A Reader's Guide. *PostGraduate Medical Journal*. 1996;72(845):1-5.
210. Podrebarac T, Tugwell P. A Reader's Guide to the Evaluation of Causation. *PostGraduate Medical Journal*. 1996; 72(845):131-137.
211. Tugwell P. Economic Evaluation of Management of Pain in Osteoarthritis. *Drugs* 50 (Suppl) 1996; 48-56.

212. Torrance G, Blaker D, Detsky A, Kennedy W, Schubert F, Memon D, Tugwell P, Konchak R, Hubbard E, Firestone T. Canadian Guidelines for Economic Evaluation of Pharmaceuticals. *PharmacoEconomics* 1996 Jun; 9(6) 535-559.
213. Tugwell P, Panayi GS. The Use of Cyclosporin A Microemulsion in Rheumatoid Arthritis: Conclusions of An International Review. *British Journal of Rheumatology* 1997;36:808-811.
214. Wells G, Cranney A, Shea B, Tugwell P. Responsiveness of Endpoints in Osteoporosis Clinical Trials. *The Journal of Rheumatology* 1997;24:1230-1233.
215. Tugwell P, Ludwin D, Gent M, Roberts R, Bensen W, Grace E, Baker P. Interaction between Cyclosporin A and Nonsteroidal Anti-inflammatory Drugs. *Journal of Rheumatology* 1997;24(6):1122-1125.
216. Bennett K, Cardiel MH, Ferraz MB, Riedemann P, Goldsmith CH, Tugwell P. Community screening for rheumatic disorder: cross cultural adaptation and screening characteristics of the COPCORD core questionnaire in Brazil, Chile and Mexico. *Journal of Rheumatology* 1997 24(1):160-8.
217. Tugwell P, Ortiz Z, Griffiths B. Rheumatoid Arthritis: Emerging evidence for the benefits of early and aggressive therapy. *Dis Manage Health Outcomes* 1997 Mar; 1(3): 141-153.
218. Adachi JD, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL, Sturtridge WC, Sebaldt RJ, Steele M, Gordon M, Themeles E, Tugwell P, Roberts R, Gent M. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. *British Journal of Rheumatology* 1997;36:255-259.
219. Ortiz Z, Tugwell P, Yocum D. The design of clinical trials aimed at assessing the DC-ART properties of new molecules in rheumatoid arthritis. *Clinical and Experimental Rheumatology* 1997;17:S39-44.
220. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M. Recommendations for a Core Set of Outcome Measures for Future Phase III Clinical Trials in Knee, Hip, and Hand Osteoarthritis. Consensus Development at OMERACT III. *Journal of Rheumatology*, 1997; 24(4):799-802.
221. Cranney A, Tugwell P, Cummings S, Sambrook P, Adachi J, Silman AJ, Gillespie WJ, Felson DT, Shea B, Wells G. Osteoporosis Clinical Trials Endpoints: Candidate Variables and Clinimetric Properties. *Journal of Rheumatology*, 1997;24(6):1222-9.
222. Cranney A, Tugwell P, Shea B, Wells G. Implications of OMERACT Outcomes in Arthritis and Osteoporosis for Cochrane Metaanalysis. *Journal of Rheumatology*, 1997;24(6):1206-7.
223. Tugwell P, Dennis D, Weinstein A, Wells G, Shea B, Nichol G, Hayward R, Lightfoot R, Baker P, Steere A. Laboratory Evaluation in the Diagnosis of Lyme Disease Clinical Guideline Part 2. *Annals of Internal Medicine*, 1997;127(12):1109-1123.
224. Boers M, Tugwell P, Brooks P. Progress Towards Optimal Trial End-Points in Rheumatoid Arthritis. *BioDrugs* 1997; 7(1): 40-50.
225. Stein M, Pincus T, Yocum D, Tugwell P, Wells G, Gluck O, Kraag G, Torley H, Tesser J, McKendry R, Brooks R, for the Methotrexate-Cyclosporine Combination Study Group. Combination Treatment of Severe Rheumatoid Arthritis with Cyclosporine and Methotrexate for Forty-Eight Weeks. *American College of Rheumatology* 1997; 40(10): 1843-1851
226. Nichol G, Shea B, Dennis DT, Steere AC, Lightfoot R, Wells G, Tugwell P. Different test-treatment strategies for patients with possible Lyme disease. A cost-effectiveness analysis. *Annals of Internal Medicine*, 1998;128(1): 37-48.

227. American College of Physicians. Guidelines for Laboratory Evaluation in the Diagnosis of Lyme Disease(Clinical Guidelines Part 1). *Annals of Internal Medicine* 1997;127(12):1106-1108.
228. Boers M, Brooks P, Strand V, Tugwell P. The OMERACT Filter for Outcome Measures in Rheumatology. *Journal of Rheumatology* 1998;25(2):198-9.
229. Ortiz A, Shea B, Suarez-Almazor ME, Moher D, Wells G. The Efficacy of Folic Acid and Folinic Acid in Reducing Methotrexate Gastrointestinal Toxicity in Rheumatoid Arthritis. A Metaanalysis of Randomized Controlled Trials. *Journal of Rheumatology* 1998;25(1):36-43.
230. Cranney A, Tugwell P. The Use of Neoral in Rheumatoid Arthritis. *Rheumatic Disease Clinics of North America* 1998;24(3):479-488.
231. O'Connor A, Tugwell P, Wells G, Elmslie T, Jolly E, Hollingworth G, McPherson R, Bunn H, Graham, Drake E. A Decision Aid for Women Considering Hormone Therapy After Menopause: Decision Support Framework and Evaluation. *Patient Education and Counseling* 1998;33:267-279.
232. O'Connor A, Tugwell P, Wells G, Elmslie T, Jolly E, Hollingworth G, McPherson R, Drake E, Hopman W, MacKenzie T. Randomized Trial of a Portable, Self-administered Decision Aid for Postmenopausal Women Considering Long-term Preventive Hormone Therapy. *Medical Decision Making* 1998;18:295-303.
233. Michaud G, McGowan J, van der Jagt R, Wells G, Tugwell P. Are Therapeutic Decision Supported by Evidence from Health Care Research. *Arch Intern Med* 1998;158:1665-1668.
234. Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: A survey. *Journal of Rheumatology*, 1998;25(12);2331-2338.
235. Papaioannou A, Parkinson W, Adachi J, O'Connor A, Jolly E, Tugwell P, Bedard M. Women's decisions about hormone replacement therapy after education and bone densitometry. *CMAJ*, 1998;159(10);1253-1257.
236. Jadad A, Cook D, Jones A, Klassen T, Tugwell P, Moher M, Moher D. Methodology and Reports of Systematic Reviews and Meta-analyses: A Comparison of Cochrane Reviews with Articles Published in Paper-Based Journals. *JAMA*, 1998;280(3);278-280.
237. Moher D, Pham B, Jones A, Cook D, Jadad A, Moher M, Tugwell P, Klassen T. Does Quality of Reports of Randomised Trials Affect Estimates of Intervention Efficacy Reported in Meta-Analyses? *The Lancet*, 1998;352;609-613.
238. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. *Br J Rheumatol*, 1998;37;612-9.
239. Clark P, de la Pena F, Gomez Garcia F, Orozco JA, Tugwell P. Risk factors for osteoporotic hip fractures in Mexicans. *Archives of Medical Research*, 1998;29(3); 253-257.
240. Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. *Journal of Rheumatology*, 1999;26(5); 1176-1186.
241. Cranney A, Coyle D, Welch V, Lee K, Tugwell P. Current controversies in cost effectiveness analysis of osteoporosis therapies. *Journal of Rheumatology*, 1999;26(11); 2300-2302.
242. O'Connor AM, Drake ER, Fiset V, Graham ID, Laupacis A, Tugwell P. The Ottawa Patient Decision Aids. *Effective Clinical Practice*, 1999;Vol2(4);163-170.

243. Cranney A, Welch V, Tugwell P, Wells G, Adachi JD, McGowan J, Shea B. Responsiveness of endpoints in osteoporosis clinical trials - An update. *Journal of Rheumatology*, 1999;26-1; 222-228.
244. O'Connor A, Wells G, Tugwell P, Laupacis A, Elmslie T, Drake E. The effects of an "explicit" values clarification exercise in a woman's decision aid regarding postmenopausal hormone therapy. *Health Expectations*, 1999;2;21-32.
245. Wells G, Boers M, Shea B, Tugwell P, Westhovens R, Suarez-Almazor M, Buchbinder R. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: Preliminary findings in the generic health, OMERACT study. *Journal of Rheumatology*, 1999: 26-1;217-221.
246. Ortiz Z, Shea B, Dieguez MG, Boers M, Tugwell P, Boonen A, Wells G. The responsiveness of generic quality of life instruments in rheumatic diseases. A systematic review of randomized controlled trials. *Journal of Rheumatology*, 1999;26-1;210-216.
247. Gazarian M, Tugwell P, Boers M, Bombardier C, Brooks P, Day R, Strand V, Wells G. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT drug toxicity working party. *Journal of Rheumatology*, 1999;26-1; 207-209.
248. Boers M, Brooks P, Strand V, Tugwell P. Introduction - OMERACT IV: Fourth International Consensus Conference on Outcome Measures in Rheumatology. *Journal of Rheumatology*, 1999;26-1;199-200.
249. Gabriel S, Tugwell P, O'Brien B, Yelin E, Drummond M, Ruff B, Brooks P, Bombardier C, Boers M. Report of the OMERACT task force on economic evaluation. *Journal of Rheumatology*, 1999;26-1;203-206.
250. Jerome D, Tugwell P. Skills development in rheumatology undergraduate and postgraduate curricula. *Journal of Rheumatology*, 1999;26(Suppl 55);38-40.
251. Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, Gordon C, Isenberg DA, Klippel JH, Petri M, Simon L, Tugwell P, Wolfe F. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains. *Journal of Rheumatology*, 1999;26-2;504-507.
252. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. *Journal of Rheumatology*, 1999;26-2; 490-497.
253. Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. *Journal of Rheumatology*, 1999;26-2;484-489.
254. Pham B, Cranney A, Boeres M, Verhoevan AC, Wells G, Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. *Journal of Rheumatology*, 1999;26-3;712-716.
255. Van der Heijde D, Van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA, Adebajo A, Van Albada B, Amor B, Barlow J, Benevolenskaya L, Bird H, Boers M, Boonen A, Bosi-Ferraz M, Braun J, Brooks P, Bruckel J, Burgos-Vargas R, Collantes-Estevez B, Clegg D, Darmawan J, Dekker-Saeyns A, Dijkmans B, Ebringer A, Edmonds J, Engelman J, Feltelius N, Flato N, Geher P, Gran J, Guillemin F, Husby G, Juhlin R, Kirazli Y, Klareskog L, Kvien T, Leirisalo-Repo M, Linssen A, Michel B, Mielants H, Olivieri I, Peloso P, Van Riel P, Rogers F, Russell A, Stanislawska-Biernat E, Salvarini C, Stucki G, Sturrock R, Thomson G, Tugwell P, Veys E, Zeidler H. Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. *Journal of Rheumatology*, 1999;Vol 26(4);945-947. Cush JJ, Tugwell P, Weinblatt M, Yocum D. US

- consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. *Journal of Rheumatology*, 1999;26-5;1176-1186.
256. Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, Suarez-Almazor ME. A meta-analysis on the use of bisphosphonates in corticosteroid induced osteoporosis. *Journal of Rheumatology*, 1999;26-5;1148-1157.
 257. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis. *Rheumatology*, 1999; 38(8);789-790.
 258. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G. on behalf of the Leflunomide Rheumatoid Arthritis Investigators Group. Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. *Arthritis & Rheumatism*, September 1999: Vol 42(9),1870-1878.
 259. O'Connor AM, Fiset V, DeGrasse C, Graham ID, Evans W, Stacey D, Laupacis A, Tugwell P. Decision aids for patients considering options affecting cancer outcomes: Evidence of efficacy and policy implications. *National Cancer Institute Monographs*, 1999;25;67-80.
 260. Moher D, Klassen T, Cook D, Jadad A, Tugwell P, Moher M, Jones A, Pham B. Assessing the quality of reports of randomized controlled trials included in meta-analyses: attitudes, practice, evidence, and guides. *Health Technology Assessment*, 1999; 3(12); i-iv, 1-98.
 261. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV Outcome Measures in Rheumatology Lupus 2000; 9(5):322-7.
 262. Tugwell P, Boers M, Cranney A. Evidence-Based Rheumatology In: *Textbook of Rheumatology*, 6th Edition, Kelley WN, Harris ED, Jr, Ruddy S, Sledge CB, Editors. W.B. Saunders Company, Philadelphia; 2001.
 263. McAuley L, Pham B, Tugwell P, Moher, D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? *Lancet*, 2000: 356,1228-1232.
 264. Rostom A, Maetzel A, Tugwell P, Wells G. Ulcer disease and non-steroidal anti-inflammatory drugs: etiology and treatment. *Evidence Based Gastroenterology and Hepatology*. BMJ Books, 1999. Chapter 4(91-117).
 265. Cranney A, Dube C, Rostom A, Tugwell P, Wells G. Metabolic bone disease in gastrointestinal disorders: prevalence, prevention and treatment. *Evidence Based Gastroenterology and Hepatology*. BMJ Books, 1999. Chapter 11(204-220).
 266. Michaud G, Berthiaume L, Debalays E, McGowan J, O'Connor A, Jolly E, Wells G, Elmslie T, Tugwell P. Qualitative/quantitative descriptors of risk and benefit of hormone replacement therapy. *AJM*, 1999. (Submitted)
 267. Boers M, Brooks P, Simon L, Strand V, Tugwell P. Recent developments for optimal endpoints in rheumatoid arthritis clinical studies. *Biodrugs*, updated 1999: Jan 7(1)40-50.
 268. Cranney A, Coyle D, Welch V, Lee KM, Tugwell P. A review of economic evaluation in osteoporosis. Review article. *Arthritis Care and Research*. Volume 12, No. 6: 425-434, December 1999.

269. Cranney A, Coyle D, Welch V, Lee K, Tugwell P. Current controversies in cost effectiveness analysis of osteoporosis therapy. *J Rheumatol* 1999 Nov; 26(11):2300-2.
270. Ortiz Z, Shea B, Suarez-Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). *The Cochrane Library*, Issue 4, 1999. Oxford: Update Software.
271. Maetzel A, Wong A, Bombardier C, Strand V, Tugwell P, Wells G. Meta-analysis of treatment termination rates among RA patients receiving slow-acting anti-rheumatic agents. *Rheumatology*, 2001. In Press
272. Forster A, Tugwell P, van Walraven C. Practice environment and quality of care: do hospital occupancy rates effect quality of care? *Journal of Quality in Clinical Practice*. 2000 Vol. 2 (2): 69-74.
273. Osiri M, Shea B, Tugwell P. Health-related quality of life (HRQOL) in rheumatoid arthritis: its relevance to patient care and health economics. *Topics in Health Economics*. February 2000; 4-10.
274. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A, leflunomide rheumatoid arthritis investigators group. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis. Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. *Arthritis & Rheumatism*, 2000: Vol 43(3);506-514.
275. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. *Osteoporosis International*, 2000; 11(9):727-38..
276. Tugwell P. Pharmacoeconomics of drug therapy for rheumatoid arthritis. *Rheumatology*, 2000; 39(suppl. 1): 43-47.
277. Tugwell P, Salinas A. Manual de epidemiologia para reumatologos. Metodologia de la investigacion en reumatologia clinica. Analisis de decision en Reumatologia. Capitulo 13: 207-218, 2000.
278. Molenaar E, Boers M, Brooks P, Simon L, Strand V, Tugwell P. Recent developments for optimal endpoints in rheumatoid arthritis clinical studies. *Journal of Disease Management and Health Outcomes*. August 2000; 8(2): 87-97.
279. Brosseau L, Welch V, Wells G, Tugwell P, de Bie R, Gam A, Harman K, Shea B, Morin M. Low level laser therapy for osteoarthritis and rheumatoid arthritis: a meta-analysis. *Journal of Rheumatology*, 2000; 27:1961-1969.
280. Tugwell P, Welch V, Wells G, Shea B, Suarez-Almazor M. Efficacy and toxicity of old and new DMARDs. *Annals of the Rheumatic Diseases*, 2000, 59, Suppl. 1, i32-5
281. Rostom A, Wells G, Tugwell P, Welch V, Dube C, McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. *J Rheumatol* 2000 Sep; 27(9):2203-14.
282. Hulka BS, Kerkvliet NL, Tugwell P. Experience of a scientific panel formed to advise the federal judiciary on silicone breast implants. *New England Journal of Medicine*, 2000;342(11); 812-815.
283. Maetzel A, Wong A, Bombardier C, Strand V, Tugwell P, Wells G. Meta-analysis of treatment termination rates among RA patients receiving slow-acting anti-rheumatic agents. *Rheumatology* 2000; 39(9):975-981

284. Brosseau L, Welch V, Wells G, deBie R, Gam A, Harman K, Morin M, Shea B, Tugwell P. Low level laser therapy (classes I, II and III) in the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews [computer file]. (2):CD002049,2000.
285. Brosseau L, Welch V, Wells G, deBie R, Gam A, Harman K, Morin M, Shea B, Tugwell P. Low level laser therapy (classes I, II and III) for the treatment of osteoarthritis. Cochrane Database of Systematic Reviews [computer file]. (2):CD002046, 2000.
286. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews [computer file]. (2):CD001983, 2000.
287. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, Suarez-Almazor ME, Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews [computer file].(2):DC001347,2000.
288. Suarez-Almazor MR, Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for rheumatoid arthritis. Cochrane Database of Systematic Reviews [computer file].(2):CD001157, 2000.
289. Saenz A, Aulsebrook M, Shea B, Wells G, Welch V, Tugwell P. Pharmacotherapy for Behcet's syndrome. Cochrane Database of Systematic Reviews [computer file].(2):CD001084, 2000.
290. Wells G, Hagenauer D, Shea B, Suarez-Almazor ME, Welch VA, Tugwell P. Cyclosporine for rheumatoid arthritis. Cochrane Database of Systematic Reviews [computer file].(2):CD001083, 2000.
291. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for rheumatoid arthritis. Cochrane Database of Systematic Reviews [computer file]. (2):CD000959,2000.
292. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database of Systematic Reviews [computer file]. (2):CD000958, 2000.
293. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews [computer file]. (2):CD000957,2000.
294. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews [computer file]. (2):CD000952, 2000.
295. Hagenauer D, Welch V, Shea B, Tugwell P, Wells GA. Fluoride for Treating Postmenopausal osteoporosis (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2000.
296. Welch V, Brosseau L, Shea B, McGowan J, Wells G, Tugwell P. Thermotherapy for Treating Rheumatoid Arthritis (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2000.
297. Milne S, Welch V, Brosseau L, Saginur M, Shea B, Tugwell P, Wells GA. Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2000.
298. Osiri M, Welch V, Brosseau L, Shea B, McGowan J, Tugwell P, Wells GA. Transcutaneous Electrical Nerve Stimulation for Knee Osteoarthritis (Cochrane Review). The Cochrane Library, Oxford: Update Software, 2000.

299. Robinson V, Brosseau L, Shea B, McGowan J, Wells G, and Tugwell P. Thermotherapy for treating rheumatoid arthritis (Cochrane Review). The Cochrane Library [4]. 2001. Oxford, Update Software.
300. Osiri M, Deesomchok U, Tugwell P. Evaluation of functional ability of Thai patients with rheumatoid arthritis by the use of a Thai version of the Health Assessment Questionnaire. *Journal of Rheumatology*, 2001; 40:555-558.
301. Neufeld V, MacLeod S, Tugwell P, Zakus D, Zarowsky C. The rich-poor gap in global health research: challenges for Canada. *Canadian Medical Association Journal*, Apr. 17 2001; 164(8).
302. Cranney A, Coyle D, Pham B, Tetroe J, Wells G, Jolly E, Tugwell P. The validity of patient preferences in osteoporosis. *J Rheumatol* Jan 2001; 28(1) 132-7.
303. Cranney A, Welch V, Wells G, Adachi JD, Shea B, Simon L, Tugwell P. Discrimination of change in osteoporosis outcomes. *J Rheumatol* 2001; 28:413-21.
304. Cranney A, Guyatt GH, Wells GA, Tugwell P. Systematic Reviews of Randomized Trials in Osteoporosis: an Introduction. Submitted to *J Clin Endocrinol Metab*.
305. Fitt N, Mitchell S, Cranney A, Gulenchyn K, Huang M, Tugwell P. The impact of bone densitometry on the treatment of osteoporosis. *Journal of the Canadian Medical Association*, 2001; 164(6): 777-781.
306. Tugwell P, Wells G, Peterson J, Shea B, Welch V, Page J, Davison C, McGowan J. Silicone breast implants in relation to connective tissue disorders: rheumatologic clinical epidemiological results of a court appointed national science panel. *Arthritis and Rheumatism*, Vol.44, No.11, Nov.2001, pp 2477-84.
307. Clinch J, Tugwell P, Wells G, Shea B. Individualized Functional Priority Approach to the Assessment of Health Related Quality of Life in Rheumatology. *J Rheumatol* 2001; 28:445-51
308. Coyle D, Welch V, Shea B, Gabriel S, Drummond M, Tugwell, P. Issues of Consensus and Debate for Economic Evaluation in Rheumatology. *J Rheumatol* 2001; 28:642-7.
309. Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for shoulder pain. *Physical Therapy*, October 2001;81:1719-1730.
310. Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions: Methodology. *Physical Therapy*, October 2001;81:1629-1640.
311. Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. *Physical Therapy*, October 2001;81:1641-1674.
312. Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for neck pain. *Physical Therapy*, October 2001;81:1701-1717.
313. Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for knee pain. *Physical Therapy*, October 2001;81:1675-1700.
314. Brosseau L, Casimiro L, Robinson V, Milne S, Shea B, Judd M, Wells G, and Tugwell P. Therapeutic ultrasound for treating patellofemoral pain syndrome (Cochrane Review). The Cochrane Library [5]. 2001. Oxford, Update Software.
315. Brosseau L, Casimiro L, Robinson V, Milne S, Shea B, Judd M, Wells G, and Tugwell P. Deep transverse massage frictions for treating tendonitis (Cochrane Review). The Cochrane Library [5]. 2001. Oxford, Update Software.

316. Shea B, Moher D, Graham I, Pham B, Tugwell P. A Comparison of the Quality of Reporting of Cochrane Collaboration and Paper-Based Published Systematic Reviews. *Evaluation and the Health Professions*, Vol. 25 No.1, March 2002: 116-129.
317. Papadimitropoulos E, Wells G, Shea B, Gillepsie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood CE, Guyatt G, et al. A Meta-Analysis of the Efficacy of Vitamin D Treatment in Preventing Osteoporosis in Postmenopausal Women. *Endocr Rev*. 2002 Aug; 23(4):560-9.
318. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. *Endocrine Reviews*. 2002 Aug;23(4):570-8.
319. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, Ortiz Z, Peterson J, Adachi JD, Tugwell P, Guyatt G, et al. Meta-Analysis of Calcium Supplementation for the Prevention of Postmenopausal Osteoporosis. *Endocr Rev*. 2002 Aug; 23(4):552-9.
320. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G. Meta-analysis of alendronate for the treatment of postmenopausal women. *Endocr Rev*: 2002 Aug; 23(4):508-16.
321. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi JD, Waldegger L, Guyatt GH. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis. *Endocr Rev*. 2002 Aug;23(4):540-51.
322. Cranney A, Tugwell PS, Zytaruk N, Robinson V, Weaver B, Adachi JD, Wells GA, Shea B, Guyatt G. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis. *Endocr Rev*. 2002 Aug;23(4):524-8.
323. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A, Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocrine Reviews*. 2002 Aug;23(4):529-39.
324. Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi R, Shea G, Tugwell P. Meta-Analysis of etidronate for the treatment of postmenopausal osteoporosis. *Osteoporosis Int*. 12:140-151.
325. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G. A Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis. *Endocr Rev*. 2002 Aug;23(4):517-23.
326. Laupacis A, Bourne R, Rorabeck C, Feeny D, Tugwell P, Wong C. A randomized trial comparing cemented with non-cemented hip arthroplasty: 6 to 11 year follow-up. *Journal of Bone and Joint Surgery* October 2002. Vol.84-A,(10) 1823.
327. Torrance GW, Raynauld JP, Walker V, Goldsmith CH, Bellamy N, Band PA et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. *Osteoarthritis & Cartilage* 2002; 10(7):518-527.
328. Brosseau L, Robinson V, Pelland L, Casimiro L, Milne S, Judd M, Wells G, Tugwell P, Shea B. Efficacy of Thermotherapy for Rheumatoid Arthritis: A Meta-Analysis. *Physical Therapy Reviews* 2002; 7: 5-15

329. Brosseau L, Milne S, Robinson V, Marchand S, Shea B, Wells G, and Tugwell P, The effectiveness of transcutaneous electrical nerve stimulation (TENS) for chronic low back pain: a meta-analysis., *Spine* 27:596 (2002).
330. Brosseau L, Robinson V, Léonard G, Casimiro L, Pelland L, Wells G, and Tugwell P, Efficacy of balneotherapy for rheumatoid arthritis: a meta-analysis., *Physical Therapy Reviews* 7:67 (2002).
331. Casimiro L, Brosseau L, Robinson V, Milne S, Judd M, Wells G, and Tugwell P. Acupuncture for the symptomatic of rheumatoid arthritis (Cochrane Review). The Cochrane Library [4]. 2002. Oxford, Update Software.
332. Casimiro L, Brosseau L, Robinson V, Milne S, Judd M, Wells G, and Tugwell P. Ultrasound for the symptomatic of rheumatoid arthritis (Cochrane Review). The Cochrane Library [4]. 2002. Oxford, Update Software.
333. Pelland L, Brosseau L, Casimiro L, Robinson V, Wells G, and Tugwell P. Electrical stimulation in the treatment of rheumatoid arthritis (Cochrane Review). The Cochrane Library [4]. 2002. Oxford, Update Software.
334. Welch V, Brosseau L, Peterson J, Shea B, Tugwell P, and Wells G. Therapeutic ultrasound for osteoarthritis of the knee (Cochrane Review). The Cochrane Library [4]. 2002. Oxford, Update Software.
335. Brosseau L, MacLeay L, Robinson V, Wells G, and Tugwell P. Intensity of exercise for osteoarthritis. *Cochrane Database of Systematic Reviews*. 2003;(2):CD004260
336. Bonaiuti D, Shea B, Iovine R, Negrini S, Robinson V, Kemper, HC, Wells, G, Tugwell P, Cranney A. Exercise for preventing and treating osteoporosis in postmenopausal women. *Cochrane Database of Systematic Reviews*. 2002;(3):CD000333.
337. Egan M, Brosseau L, Farmer M, Ouimet M.A, Rees S, Wells G, and Tugwell P. Splints/orthoses in the treatment of rheumatoid arthritis (Cochrane Review). The Cochrane Library [1]. 2003. Oxford, Update Software
338. Milne S, Brosseau L, Noel M.J, Drouin H, Davis J, Wells G, and Tugwell P. Continuous passive motion following total knee arthroplasty *Cochrane Database of Systematic Reviews* 2003;(2):CD004260
339. Tugwell P, Qualman A, Judd M, et al. Workshop report: Knowledge Translation of Musculoskeletal Health Research. *Journal of Rheumatology* 2003 Mar;30(3):575-8
340. Osiri M, Suarez-Almazor ME, Wells GA, Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. *Annals of the Rheumatic Diseases* 2003 Apr;62(4):316-21
341. Rostom A, Maetzel A, Tugwell P, Wells G. Ulcer disease and non-steroidal anti-inflammatory drugs: etiology and treatment. *Evidence Based Gastroenterology and Hepatology*. BMJ Books 2nd Edition. In Press.
342. Blumenauer B, Coyle D, Tugwell P. Pharmacoeconomics of long-term treatment of rheumatoid arthritis. *Expert Opinion on Pharmacotherapy*. 2002 Apr;3(4):417-22
343. Russak S, Croft J, Furst D, Hohlbauck A, Liang M, Moreland L, Ofman J, Paulus H, Simon L, Weisman M, Tugwell P. The use in rheumatoid arthritis (RA) health-related quality of life patient questionnaires in clinical practice: Lessons learned. *Arthritis & Rheumatism (Arthritis Care and Research)*. 2003 Aug 15;49(4): 574-584.

344. Brosseau L, Tugwell P, Wells G, Egan M, Dubouloz C.J, Casimiro L, Robinson V, Pelland L, and Lamb M, Ottawa Panel evidence-based clinical practice guidelines for therapeutic exercises and manual therapy in the treatment of rheumatoid arthritis., *Physical Therapy* (submitted): (2003).
345. Brosseau L, Yonge K, Marchand S, Robinson V, Wells G, and Tugwell P, Efficacy of transcutaneous electrical nerve stimulation for osteoarthritis of the lower extremities: a meta-analysis., *Physical Therapy Reviews* (submitted): (2003).
346. Brosseau L, Yonge K, Marchand S, Robinson V, Wells G, and Tugwell P. Efficacy of thermotherapy for osteoarthritis: a systematic review., *Physical Therapy Reviews* (submitted): (2003).
347. Brosseau L, Yonge K, Marchand S, Robinson V, Wells G, and Tugwell P. Efficacy of transcutaneous electrical nerve stimulation (TENS) for rheumatoid arthritis: a systematic review (Cochrane Review). *The Cochrane Library* (submitted). 2003.
348. Brosseau L, Yonge K, Marchand S, Robinson V, Wells G, and Tugwell P. Efficacy of thermotherapy for osteoarthritis: a systematic review (Cochrane Review). *The Cochrane Library* (submitted). 2003. Oxford, Update Software.
349. Brosseau L, Pelland L, MacLeay L, Robinson V, Wells G, and Tugwell P, Efficacy of therapeutic exercise for osteoarthritis: a meta-analysis., *Arthritis Care and Research* (submitted): (2003).
350. Dubouloz C.J, Brosseau L, Egan M, Boudreau M, Robitaille J, Robinson V, Wells G, and Tugwell P, Efficacy of patient education for osteoarthritis: a meta-analysis., *American Journal of Occupational Therapy* (submitted): (2003).
351. Brosseau L, MacLeay L, Casimiro L, Pelland L, Wells G, Tugwell P, and McGowan J, Efficacy of balneotherapy for osteoarthritis of the knee: a systematic review, *Physical Therapy Reviews* 2002; 7:209-222.
352. Brosseau L, Yonge K, Marchand S, Robinson V, Wells G, and Tugwell P. Efficacy of transcutaneous electrical nerve stimulation (TENS) for rheumatoid arthritis: a systematic review., *Physical Therapy Reviews* 2002;7:199-208.
353. Brosseau L, Yonge K, Marchand S, Robinson V, Wells G, and Tugwell P. Efficacy of transcutaneous electrical nerve stimulation (TENS) for rheumatoid arthritis: a systematic review (Cochrane Review). *The Cochrane Library* (in press). 2003. Oxford, Update Software.
354. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, Van Riel PL, Tugwell P. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology*. 2003 Feb;42(2):244-57
355. Blumenauer B, Cranney A, Clinch J, Tugwell P. Quality of live in patients with rheumatoid arthritis: which drugs might make a difference? *Pharmacoeconomics*. 2003;21(13):927-40
356. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. *Journal of Rheumatology*. 2003 Jun;30(6):1182-90
357. Wells G, Boers M, Shea B, Anderson J, Felson D, Johnson K, Kirwan J, Lassere M, Robinson V, Simon L, Strand B, van Riel P, Tugwell P. MCID/Low disease Activity State Workshop: low disease activity state in rheumatoid arthritis. *Journal of Rheumatology*. 2003 May;30(5):1110-1

358. Wells G, Boers M, Shea B, Anderson J, Felson D, Johnson K, Kirwan J, Lassere M, Robinson V, Simon L, Strand B, van Riel P, Tugwell P. MCID/Low disease Activity State Workshop: summary, recommendations, and research agenda. *Journal of Rheumatology*. 2003 May;30(5):1115-8
359. O'Connor AM, Drake ER, Wells GA, Tugwell P, Laupacis A, Elmslie T. A survey of the decision-making needs of Canadians faces with complex health decision. *Health Expectations*. 2003 Jun;6(2):97-109
360. Brosseau L, Yonge KA, Robinson F, Marchand S, Judd M, Wells G, Tugwell P. Transcutaneous electrical nerve stimulation (TENS) for the treatment of rheumatoid arthritis in the hand. *Cochrane Database of Systematic Reviews*. 2003;(3):CD004287
361. Coyle D, Cranney A, Tugwell P. Economic evaluation of the norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms. *Pharmacoeconomics*. 2003;21(9):661-9
362. Brosseau L, Welch V, Wells G, deBie R, Gam A, Harman K, Morin M, Shea B, Tugwell P. Low level laser therapy (classes I, II and III) in the treatment of rheumatoid arthritis. [update of Cochrane Database of Systematic Reviews [computer file]. (2):CD002049,2000] *Cochrane Database of Systematic Reviews*. 2003;(2):CD002046
363. Gabriel S, Drummond H, Maetzel A, Boers M, Coyle D, Welch V, Tugwell P, Patient Perspective Group. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. *Journal of Rheumatology*. 2003 Apr;30(4):886-90
364. Maetzel A, Tugwell P, Boars M, Guillemin F, Coyle D, Drummond M, Wong JB, Gabriel SE, OMERACT 6 Economics Research Group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. *Journal of Rheumatology*. 2003 Apr;20(4):891-6
365. Cranney A, Tugwell P, Wells G, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. *Endocrine Reviews*. 2002 Aug;23(4):496-507

PEER-REVIEWED GRANTS: (Since 1990)

1. New approaches to pain measurement in arthritis. With L. Hart, C. Goldsmith. Funding: \$100,000, Ontario Ministry of Health, 1991-1993.
2. Controlled trial of hydrotherapy in rheumatoid arthritis. With L. Hart, C. Goldsmith, J. Chapman. Funding: \$125,000, NHRDP, 1991-1993.
3. Pilot study to evaluate a portable, self-administered decision aid for women considering long-term hormone replacement therapy. With O'Connor A, Wells G, Elmslie T. Funding: \$96,000.00, Institute for Clinical Evaluation Sciences, Sunnybrook Health Science Centre, 1994-1995.
4. OMERACT: Outcome Measures in Rheumatoid Arthritis Clinical Trials. Principal Coordinator. \$300,000 from various government, industry and charity sponsors, 1991-.
5. Development and evaluation of evidence-based decision aids for seniors making choices about hormone replacement therapy. With O'Connor A, Carswell A, Ross M, Wells G, Wolfson M, Dalziel W, Elmslie T. NHRDP, Health Canada. \$226,828, 1995-1996.
6. Development of a practitioner information aid and practitioner-patient interaction guide to support decision making about long-term preventive hormone replacement therapy. With A.O'Connor A, Elmslie T, Graham I, Wells G, Bunn H, Hollingworth G, Jolly E, McPherson R, Laupacis A. Institute for Clinical Evaluation Sciences, Sunnybrook Health Science Centre. \$91,140, 1995-1996.
7. A randomized study of cemented versus non-cemented hip prostheses. With A. Laupacis, R. Bourne, C. Rorabeck, S. Dalice. Funding: \$607,182.00, Medical Research Council of Canada, extended to March 31, 1997.
8. Canadian Cochrane Network and Centre. With R.B. Haynes et al. Funding: \$100,000 from the Medical Research Council of Canada, 1995-1999.
9. Quality assessment of clinical trials. With D. Moher et al. Funding: \$250,000.00, Great Britain National Health Service, 1995-1997.
10. Decision support technologies. Co-principal investigator with A. Laupacis and A. O'Connor on the Medical Research Council Program Grant and on three of the component grants: "Long-term hormone replacement therapy: an evidence-based approach to estimating the benefits, risks, costs and acceptability to post-menopausal women"; "Methodological issues in developing patient decision aids: evaluation of methods for presenting the evidence of treatment benefits and risks and clarifying values"; "Implementation and evaluation of methods and procedures for assessing changes in health states over time". Funding: \$600,000.00, Medical Research Council of Canada, 1995-1998.
11. A randomized controlled trial evaluating the impact of decision aids on informed decision making of postmenopausal women considering long-term preventative HRT. Co-principal Investigator with Annette O'Connor. Funding: \$120,000 Arthritis Society of Canada 1996-98.
12. WHO Collaborating Center for Health Technology Assessment: Needs-based Technology Assessment Tool Kit (Global). Principal Investigator. Funding: \$96,000 IDRC, 1996-98.

13. Educating health practitioners in shared decision making. With Bunn H, O'Connor A, Doucet S, Jones L. Funding \$5,000 from University Of Ottawa Teaching and Learning Grants Subcommittee. OHDEC, 1996-98.
14. CIGNA Foundation Physical Therapy Project. Principal Investigator. Tugwell P, Brosseau L, Wells G, Coyle D, Cranney A, Graham I, McGowan J. \$151,058 (US), 1999-2001.
15. Capacity building of nurses and adaptation of decision-making tools in Chile. Canadian International Development Agency. Principal Investigator. \$499,999, 1998-2002.
16. Arthritis Society Research Grant. A randomized trial to evaluate a decision aid for women with osteoporosis. With Cranney A, O'Connor A, Adachi JD, Jolly E. \$27,115, 1999-2002.
17. Council on Health Research and Development, Geneva. Development of an index to reflect health research into equity issues. Principal Investigator. 1999-2000, \$85,000.
18. Arthritis Society of Canada. Systematic evaluation of new therapies for the treatment of rheumatoid arthritis. With Wells G, Shea B, Suarez-Almazor M, Boers M, Coyle D, Maetzel A. 1998-99, \$100,000.
19. Medical Research Council of Canada. Practitioner response to evidence-based patient decision aids. With Ian Graham. 2000-2002, \$148,000.
20. Arthritis Society of Canada. A randomized controlled trial evaluating the impact of decision aids on informed decision making of post-menopausal women considering long-term preventive HRT. Co-principal Investigator. 1996-2000, \$240,000.
21. Canadian Institute of Health Research Group Grant. Decision support tools for clinicians and patients. With O'Connor A, Graham I, Stiell, Laupacis A. 2000-2003, \$616,349.
22. Royal College of Physicians and Surgeons. Development and program incorporation of evaluative tools for the essential roles and key competencies for the CANMEDS 2000 initiative. Principal Investigator, 2000-2001, \$20,350.
23. Physiotherapy Foundation of Canada. Determinants of the use of evidence-based clinical practice guidelines for the treatment of lumbar and cervical pain syndromes among physiotherapists. With Lucie Brosseau, Ian Graham, Laurie Hurley, George Wells, Vivian Welch, Bev Shea. 2000-2001, \$4,500.
24. Medical Research Council of Canada. With Brosseau L. The effect of low level laser therapy in the treatment of osteoarthritis of the hand: A pilot study. 2000, \$7,780.
25. Arthritis Society of Canada. Systematic evaluation of new therapies for the treatment of rheumatoid arthritis. Principal Investigator. 2000-2003, \$193,560.
26. CIHR. Cochrane & Knowledge Transfer Grant. Principal Investigator. 2001-2002, \$100,000.
27. Arthritis Society of Canada. With Brosseau L. The development of Evidence-Based Clinical Practice Guidelines for Physical Rehab Interventions in Treatment of Rheumatoid Arthritis. 2001-2002, \$59,450.
28. Arthritis Society of Canada. With Brosseau L. A RCT on Low-level Laser therapy in the Treatment of Osteoarthritis of Hand. 2001-2003, \$91,653.
29. University of Ottawa. Measuring & Modeling Health Inequalities in the Canadian Population & Globally. 2001-2002, \$9,600.

30. CIHR. Co-Principal Investigator with Andersson, N. ACADRE Training Grant. 2001-2004, \$1,200,000.
31. Rockefeller Foundation. Principal Investigator. Development grant from the Rockefeller Foundation. 2002-2003, \$84,000
32. CIDA/PAHO/Health Canada. Principal Investigator. International Workshop on Health Equity. 2002, \$100,000.
33. Canada Research Chair in Health Equity. 2002-2009, \$1,400,000. Canadian Foundation for Innovation. \$250,000.
34. CIHR. Principal Investigator. How do you measure an effective musculoskeletal and arthritis health consumer? 2003-2006, \$284,071.00.
35. CIHR. Principal Investigator. International Study of Low and Middle Income (LMIC) Health Research Funding Agencies' Support and Promotion of Knowledge Translation. 2003-2005, \$144,298.